Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M100907 2 mg/day for Sleep Maintenance Insomnia with Type 2 Diabetes Mellitus sub-study
2006-004942-18Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Sleep initiation and maintenance disorder and type 2 diabetes mellitus (T2DM) comparing M100907 2 mg/day with Placebo (2 arms). Primary endpoint: Change in patient-reported wake after sleep onset (pr-WASO) at 3 months. Started Jan 2007; status: terminated.
02
Drugs
volinanserin
03
Conditions
Sleep initiation and maintenance disordertype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-004942-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004942-18.